CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Fluphenazine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00929578
NCT00929578Phase 2Completed

Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis

Tufts Medical Center·interventional·Posted Jun 29, 2009·Updated Mar 31, 2017

In Brief

A Phase 2 clinical trial evaluating Fluphenazine and Placebo for Psoriasis. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

The objective of this study is to assess the safety and biologic activity of intralesional injection of fluphenazine in adult subjects with psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsImmune Control

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 29, 2009
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.0 years ago

Interventions

Fluphenazinedrug

Intralesional injection of Fluphenazine

Placebodrug

Intralesional injection of placebo